Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BIRC3 | Q13489 | 3/20 | 0.34 |
| ▸ | XIAP | P98170 | 2/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.33 |
| ▸ | TERF2 | Q15554 | 3/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8352101 | 0.90 | F2 (0.33) | BIRC3XIAPBIRC2HDAC4HDAC1 | |
| SCHEMBL12820175 | 0.90 | MEN1 (0.35) | MEN1BIRC3XIAPBIRC2HDAC4 | |
| SCHEMBL12820226 | 0.85 | XIAP (0.35) | MEN1BIRC3XIAPBIRC2HDAC4 | |
| SCHEMBL12467641 | 0.85 | PSMB9 (0.36) | HDAC1HDAC6 | |
| SCHEMBL12468417 | 0.85 | PSMB9 (0.36) | HDAC1HDAC6 | |
| SCHEMBL15849570 | 0.85 | PSMB9 (0.36) | HDAC1HDAC6 | |
| SCHEMBL12820555 | 0.82 | HDAC4 (0.35) | BIRC3XIAPBIRC2HDAC4HDAC1 | |
| SCHEMBL8003495 | 0.81 | XIAP (0.32) | BIRC3XIAPBIRC2HDAC4HDAC1 | |
| SCHEMBL8001796 | 0.80 | F2 (0.33) | BIRC3XIAPBIRC2HDAC4HDAC1 | |
| SCHEMBL12820534 | 0.80 | CTSB (0.41) | MEN1BIRC3XIAPBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011034518-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-03-24 | — | — | WO | disclosed |